矿物质皮质类受体抗剂和心力衰竭与保存的喷射分数:当前的理解和未来的前景
Xi Chen1, Meinv Huang1, Yi Chen1
1Department of Cardiology, Affiliated Hospital of Putian University, School of Clinical Medicine, Fujian Medical University, Putian, 351100, China.
Heart failure reviews
|October 16, 2024
概括
矿物质皮质类受体抗剂 (MRAs) 在心力衰竭中具有降低射出分数 (HFrEF) 的益处. 然而,在心力衰竭中,它们的有效性有所不同,这表明需要个性化治疗方法.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 矿物质皮质类受体 (MR) 在心血管健康中起作用,其过度活化有助于心力衰竭病理.
- 矿物质皮质类受体对抗剂 (MRAs) 在心力衰竭中具有降低射出分数 (HFrEF) 的有效性.
- 由于各种潜在机制,MRAs在心力衰竭与保留射出分数 (HFpEF) 中的作用和有效性仍然复杂且有争议.
研究的目的:
- 审查MR的结构和功能方面.
- 讨论MR激活和抑制的生理影响.
- 在HFpEF中探索个性化MRA治疗的潜力,使用phenomapping.
主要方法:
- 对MR结构,功能和临床试验数据的文献综述.
- 对HFpEF患者分层的现象映射概念的分析.
- 在HFpEF中检查非类固醇MRA和SGLT2抑制剂的证据.
主要成果:
- 过度激活MR有助于心脏缩,纤维化和炎症.
- 现象映射在TOPCAT试验中确定了对螺旋拉克有反应的特定HFpEF表型.
- 非类固醇MRA提供了潜在的优势,包括对HFpEF的选择性和减少副作用.
结论:
- 基于HFpEF表型的个性化MRA治疗是一种有前途的未来方向.
- 非类固醇MRA,可能与SGLT2抑制剂结合,代表了HFpEF的新治疗策略.
- 对HFpEF表型的进一步研究对于优化MRA治疗疗效至关重要.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
01:22Heart Failure Drugs: Diuretics
346
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
346
01:30Heart Failure V: Medical Management
2
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2
01:22Heart Failure Drugs: β-Blockers
320
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
320
01:29Heart Failure II: Pathophysiology
3
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
3
01:26Heart Failure Drugs: Inotropic Agents
534
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
534